



Food and Drug Administration Silver Spring MD 20993

April 2, 2019

David Nelson President Noble Pharma, LLC 4602 Domain Drive Menomonie, WI 54751

Sent via email to: <u>dnelson@noblepharmallc.com</u>

Dear Petitioner:

Your petition to the Commissioner of Food and Drug Administration requesting permission to file an ANADA for a different dosage form of a pioneer product; the name of the pioneer product is Heartgard® Plus, approved under NADA 140–971 was received by this office on 04/02/2019.

It was assigned docket number FDA-2019-P-1566. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Dynna Bigby Supervisory Administrative Proceedings Specialist Division of Dockets Management FDA/Office of the Executive Secretariat (OES)